Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease.

Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, Eguchi A, Ohyanagi M, Tsujino T, Masuyama T.

J Hypertens. 2012 Nov;30(11):2192-201. doi: 10.1097/HJH.0b013e3283581a64.

PMID:
22922699
2.

Dietary iron restriction prevents further deterioration of renal damage in a chronic kidney disease rat model.

Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, Okuhara Y, Eguchi A, Ohyanagi M, Tsujino T, Masuyama T.

J Hypertens. 2013 Jun;31(6):1203-13. doi: 10.1097/HJH.0b013e328360381d.

PMID:
23552122
3.

Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease.

Naito Y, Fujii A, Sawada H, Oboshi M, Iwasaku T, Okuhara Y, Morisawa D, Eguchi A, Hirotani S, Masuyama T.

Hypertens Res. 2015 Jul;38(7):463-70. doi: 10.1038/hr.2015.14.

PMID:
25693854
4.

Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.

Hosoya K, Minakuchi H, Wakino S, Fujimura K, Hasegawa K, Komatsu M, Yoshifuji A, Futatsugi K, Shinozuka K, Washida N, Kanda T, Tokuyama H, Hayashi K, Itoh H.

Kidney Int. 2015 Apr;87(4):749-60. doi: 10.1038/ki.2014.348.

PMID:
25337775
5.

Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.

Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T.

Hypertension. 2007 Feb;49(2):355-64.

6.

Attenuation of hypertension and renal damage in renovascular hypertensive rats by iron restriction.

Oboshi M, Naito Y, Sawada H, Iwasaku T, Okuhara Y, Eguchi A, Hirotani S, Mano T, Tsujino T, Masuyama T.

Hypertens Res. 2016 Dec;39(12):832-839. doi: 10.1038/hr.2016.93.

PMID:
27439494
7.

Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.

Tatsumoto N, Yamada S, Tokumoto M, Eriguchi M, Noguchi H, Torisu K, Tsuruya K, Kitazono T.

Am J Physiol Renal Physiol. 2015 Dec 1;309(11):F967-79. doi: 10.1152/ajprenal.00669.2014.

8.

Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.

Michea L, Villagrán A, Urzúa A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET.

Hypertension. 2008 Aug;52(2):295-300. doi: 10.1161/HYPERTENSIONAHA.107.109645.

9.
10.

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.

Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J, Meyer CJ.

Xenobiotica. 2014 Jun;44(6):570-8. doi: 10.3109/00498254.2013.852705.

11.

Mineralocorticoid receptor--Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats.

Kawarazaki H, Ando K, Shibata S, Muraoka K, Fujita M, Kawarasaki C, Fujita T.

J Hypertens. 2012 Oct;30(10):1977-85. doi: 10.1097/HJH.0b013e3283576904.

PMID:
22914542
12.

Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-β/Smad and NF-κB signaling pathway in 5/6 nephrectomized rats.

Wang DT, Huang RH, Cheng X, Zhang ZH, Yang YJ, Lin X.

Int Immunopharmacol. 2015 May;26(1):4-12. doi: 10.1016/j.intimp.2015.02.027.

PMID:
25744602
13.

Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive rats.

Naito Y, Sawada H, Oboshi M, Fujii A, Hirotani S, Iwasaku T, Okuhara Y, Eguchi A, Morisawa D, Ohyanagi M, Tsujino T, Masuyama T.

PLoS One. 2013 Oct 8;8(10):e75906. doi: 10.1371/journal.pone.0075906.

14.

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.

Aminzadeh MA, Reisman SA, Vaziri ND, Shelkovnikov S, Farzaneh SH, Khazaeli M, Meyer CJ.

Redox Biol. 2013 Oct 31;1:527-31. doi: 10.1016/j.redox.2013.10.007.

15.

Tempol, a Superoxide Dismutase-Mimetic Drug, Ameliorates Progression of Renal Disease in CKD Mice.

Ding W, Wang B, Zhang M, Gu Y.

Cell Physiol Biochem. 2015;36(6):2170-82. doi: 10.1159/000430183.

16.

Mineralocorticoid receptor activation as an etiological factor in kidney diseases.

Ueda K, Nagase M.

Clin Exp Nephrol. 2014 Feb;18(1):16-23. doi: 10.1007/s10157-013-0827-3. Review.

PMID:
23832326
17.
18.

Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats.

Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, Shibata H, Nagai Y, Mori H, Masaki T, Kobori H, Nishiyama A.

PLoS One. 2012;7(7):e41896. doi: 10.1371/journal.pone.0041896.

19.

Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.

Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T.

J Am Soc Nephrol. 2006 Dec;17(12):3438-46.

20.

Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria.

Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M, Stewart PM.

Circulation. 2005 Sep 6;112(10):1435-43.

Items per page

Supplemental Content

Support Center